Compare Eaton Corporation plc (ETN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs State Street SPDR S&P Biotech ETF — how do they compare? Eaton Corporation plc trades at $430.53 (market cap $164.88B), while State Street SPDR S&P Biotech ETF trades at $153.76 (market cap $10.11B). The key difference: Eaton Corporation plc is far larger — about 16.3× State Street SPDR S&P Biotech ETF's market cap, and Eaton Corporation plc pays a 1.04% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eaton Corporation plc for 31 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| ETN | XBI | |
|---|---|---|
Market Cap | $164.88B | $10.11B |
Volume | 2,535,086 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $459.96 | $169.55 |
52-Week Low | $315.82 | $104.99 |
Typical Hold Time | 31 Days | 38 Days |
Enterprise Value | $185.51B | — |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $430.25, down 0.25% with bearish technical signals but strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, maintains healthy margins (12.75% net income), and benefits from strategic acquisitions in data center and aerospace markets. Analyst consensus remains strongly bullish with a $502.38 price target, though technical indicators show near-term pressure with support at $418.
ETN presents a compelling growth story driven by AI data center demand and grid modernization trends, but faces execution risks from recent acquisitions and competitive pressure from peers like Vertiv. The stock's premium valuation (P/E 43.23) requires sustained earnings growth to justify, making upcoming Q3 earnings on November 5 critical for momentum.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
